Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.55 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.53 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021086 | 0.87 | NOTUM (0.69) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL397314 | 0.87 | NOTUM (0.69) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8904562 | 0.84 | SLC22A12 (0.52) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL288802 | 0.82 | SLC22A12 (0.59) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL8904564 | 0.80 | TUBB4A (0.52) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12077343 | 0.80 | ADRB2 (0.55) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL19687695 | 0.80 | CYP11B1 (0.56) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL18921803 | 0.80 | ABHD6 (0.64) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL698648 | 0.78 | NOTUM (0.62) | NOTUMHSD17B3IDO1PDK1PDK2 | |
| SCHEMBL18763042 | 0.77 | SLC22A12 (0.58) | SLC22A12TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119775198-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-112312899-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3787612-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | SLC22A12 1955/4885TUBB4A 1654/4885TUBB 1635/4885 |
| US-20220324842-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, CD47, GLI1 | SLC22A12 3064/4885TUBB4A 3171/4885TUBB 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.